Amphastar Pharmaceuticals, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $183.9M | $171.2M | $183.1M | $191.8M | $174.4M | $170.5M | $186.5M | $191.2M |
| Cost of Revenue | $90.4M | $100.8M | $97.4M | $93.2M | $87.9M | $85.3M | $99.9M | $89.3M |
| Gross Profit | $93.5M | $70.3M | $85.7M | $98.6M | $86.5M | $85.3M | $86.6M | $101.9M |
| Gross Margin | 50.8% | 41.1% | 46.8% | 51.4% | 49.6% | 50.0% | 46.5% | 53.3% |
| Operating Expenses | ||||||||
| Research & Development | $22.2M | $26.7M | $23.3M | $22.4M | $20.1M | $20.1M | $18.1M | $21.1M |
| SG&A Expense | $18.2M | $18.0M | $16.5M | $39.5M | $14.0M | $16.0M | $12.9M | $14.8M |
| Operating Income | $39.7M | $13.6M | $35.6M | $25.3M | $42.2M | $37.3M | $45.1M | $57.0M |
| Operating Margin | 21.6% | 8.0% | 19.4% | 13.2% | 24.2% | 21.9% | 24.2% | 29.8% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $38.5M | $10.1M | $31.9M | $21.5M | $39.3M | $30.9M | $44.0M | $47.7M |
| Income Tax Expense | $8.2M | $3.6M | $7.5M | $4.2M | $8.3M | $5.6M | $6.0M | $7.3M |
| Net Income | $30.3M | $6.4M | $24.4M | $17.4M | $31.0M | $25.3M | $38.0M | $40.4M |
| Net Margin | 16.5% | 3.8% | 13.3% | 9.0% | 17.8% | 14.8% | 20.4% | 21.1% |
| EPS (Basic) | $0.69 | $0.14 | $0.53 | $0.38 | $0.66 | $0.53 | $0.79 | $0.83 |
| EPS (Diluted) | $0.67 | $0.14 | $0.51 | $0.37 | $0.64 | $0.51 | $0.74 | $0.78 |
| Shares Outstanding (Basic) | 43.6M | 45.3M | 46.7M | 46.5M | 46.9M | 47.6M | 48.4M | 48.6M |
| Shares Outstanding (Diluted) | 44.2M | 46.5M | 48.2M | 47.7M | 48.1M | 49.9M | 52.1M | 51.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |